Bafna Pharmaceuticals Share Price Today

Bafna Pharmaceuticals shareholders approve AGM resolutions with 99.99% support

Shareholders approved all three AGM resolutions with 99.99% of polled votes in favour. Promoter group voting participation stood at 99.98%, while public non-institutions participated at 11.31%. Total shareholder base on record date was 7,093 with 2,36,56,335 outstanding shares. Only eight votes were cast against each resolution, all from public non-institutional investors. Director Upendar Mekala Reddy was re-appointed and cost auditor remuneration was ratified.

Bafna Pharmaceuticals FY26 Results: Net profit surges 167% YoY

Bafna Pharmaceuticals reported FY26 net profit of ₹111.00 million, up 167% YoY, with revenue rising 3.26% to ₹1,506.17 million. EBITDA margins expanded to 13.75% from 9.54%, driven by export growth of 31.29%. The company secured an ICRA credit rating upgrade and expanded capsule manufacturing capacity to 600 million units.

Bafna Pharmaceuticals Q1 Results: Net Profit Plummets 98% YoY, EBITDA Margin Shrinks to 3.31%

Bafna Pharmaceuticals reported a near-total collapse in Q1 net profit to ₹7.51 lakh from ₹338.89 lakh YoY, as revenue from operations fell 23.2% to ₹2,658.32 lakh. EBITDA declined to 9M Rupees from 51M Rupees, with the EBITDA margin shrinking sharply to 3.31% from 14.64% YoY, reflecting severe margin pressure from fixed costs and lower revenues. The company also faces GST-related demands totalling over ₹566 lakh, currently under appeal and stay orders.

Bafna Pharmaceuticals promoters report no share encumbrance in FY26

Promoters of Bafna Pharmaceuticals Limited confirmed they did not encumber any shares during the financial year ended March 31, 2026. The disclosures were submitted to BSE and NSE under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The declarations were made on behalf of the Promoter and Promoter Group.

Bafna Pharmaceuticals reconstitutes board committees after director retirement

Bafna Pharmaceuticals Limited accepted the retirement of Independent Director Mr. Navin Kumar effective June 22, 2026, following the completion of his first term. Consequently, he ceased to be the Chairman of the Audit Committee and the Nomination & Remuneration Committee. The Board reconstituted these committees effective June 23, 2026, appointing Mr. Palamadai Krishnan Sundaresan as Chairman of both, with Mrs. Ravichandran Chitra, Mr. Upendar Mekala Reddy, and Mrs. Akila Chintalapati Raju as members. The company confirmed compliance with SEBI (LODR) Regulations, 2015.

Bafna Pharmaceuticals FY26 net profit rises to ₹1,109.98 lakh

Bafna Pharmaceuticals reported a net profit of ₹1,109.98 lakh for FY26, a significant rise from ₹415.25 lakh in FY25. Revenue from operations increased to ₹15,061.74 lakh, while basic EPS improved to ₹4.69. The statutory auditors issued an unmodified opinion, noting a GST demand of ₹235.47 lakh and a refund recovery order of ₹331.09 lakh, both of which are under appeal.